Literature DB >> 7490134

Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.

C L Harris1, B P Morgan.   

Abstract

Analysis of complement inhibitory proteins present on the surface of Raji cells (obtained from the European Collection of Animal Cell Cultures; originally established from human Burkitt's lymphoma) revealed two populations of cells. These populations differed in their expression of the glycosyl-phosphatidylinositol (GPI)-anchored inhibitors CD59 and decay-accelerating factor (DAF). Two stable clones were established by limiting dilution of the original cell culture. Raji+3 expressed CD59 and DAF whereas Raji-26 expressed neither inhibitor. Both clones expressed membrane cofactor protein (MCP). Analyses of other cell surface proteins (CD19, CD35, CD48 and CD58 (transmembrane form)) revealed similar levels of expression of transmembrane proteins by both clones. However, CD48 was expressed only by Raji+3. As CD48, DAF and CD59 are all GPI-anchored molecules it is likely that a defect in the GPI-anchoring mechanism is responsible for the generation of the second population of cells. The two clones demonstrated markedly different sensitivities to complement. When equally sensitized cells from both clones were treated with normal human serum (12.5%) for 1 hr at 37 degrees, the Raji+3 clone was resistant to complement-mediated lysis, whereas approximately 70% of the Raji-26 cells were lysed. However, by using specific antibody to block the function of membrane-bound complement inhibitors, lysis of Raji+3 was demonstrated. Whilst blocking of one inhibitor only on the cell had little effect on cell killing, blocking of two or more inhibitors significantly increased cell lysis. Our results demonstrated that all three inhibitors expressed by these cells contributed to protection against classical pathway-mediated complement activation. However, whilst a limited protective role was seen for MCP, CD59 and DAF appeared to be of far more importance for protection from complement-mediated lysis via the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490134      PMCID: PMC1384011     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

Review 2.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

4.  Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.

Authors:  G D Ross; J D Lambris; J A Cain; S L Newman
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines.

Authors:  J L Cole; G A Housley; T R Dykman; R P MacDermott; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

6.  Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

7.  Anchoring of membrane proteins via phosphatidylinositol is deficient in two classes of Thy-1 negative mutant lymphoma cells.

Authors:  A Conzelmann; A Spiazzi; R Hyman; C Bron
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

8.  Complement receptor is an inhibitor of the complement cascade.

Authors:  K Iida; V Nussenzweig
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

9.  Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.

Authors:  M Bessler; P J Mason; P Hillmen; T Miyata; N Yamada; J Takeda; L Luzzatto; T Kinoshita
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

10.  Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b.

Authors:  T Seya; J R Turner; J P Atkinson
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  4 in total

1.  Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP).

Authors:  J M Pérez De La Lastra; C W Van Den Berg; R Bullido; F Almazán; J Domínguez; D Llanes; B P Morgan
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

2.  Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Authors:  C L Harris; O B Spiller; B P Morgan
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

3.  Regulatory Architecture of the RCA Gene Cluster Captures an Intragenic TAD Boundary, CTCF-Mediated Chromatin Looping and a Long-Range Intergenic Enhancer.

Authors:  Jessica Cheng; Joshua S Clayton; Rafael D Acemel; Ye Zheng; Rhonda L Taylor; Sündüz Keleş; Martin Franke; Susan A Boackle; John B Harley; Elizabeth Quail; José Luis Gómez-Skarmeta; Daniela Ulgiati
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

4.  Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria.

Authors:  Lingjun Zhang; Jin Y Chen; Cassandra Kerr; Brian A Cobb; Jaroslaw P Maciejewski; Feng Lin
Journal:  Leukemia       Date:  2020-08-19       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.